In conclusion, the results of our meta-analysis suggest that in patients with PBC, PPAR agonists are safe, well-tolerated, and associated with improvements in liver-associated biomarkers and multiple metabolic parameters. The gene discussed is PPARA; the disease is primary biliary cholangitis.